ISO 10993 Biocompatibility Testing for Transdermal Patches

Author:Kangdi 21-05-2026

If you're sourcing transdermal patches for medical or cosmetic use, biocompatibility testing is one of the most critical steps in the product qualification process. Under ISO 10993—the international standard for the biological evaluation of medical devices—every material that contacts human skin must undergo rigorous safety testing.

Failing to verify ISO 10993 compliance can result in rejected shipments, regulatory penalties, or—worst case—harm to end users. This guide explains exactly what ISO 10993 testing covers, which tests apply to transdermal patches, and how to verify your supplier's compliance.

1. What Is ISO 10993?

ISO 10993 is a multi-part series of standards published by the International Organization for Standardization (ISO) that defines the requirements for evaluating the biocompatibility of medical devices. It covers everything that contacts human tissue—from surgical implants to topical patches.

The standard is adopted by regulatory bodies worldwide, including:

• FDA (USA) — references ISO 10993 in 21 CFR Part 820
• CE Marking (European Union) — required under MDR 2017/745
• PMDA (Japan) and Health Canada
• TGA (Australia) and other national regulators

For transdermal patches, the relevant parts of ISO 10993 cover skin contact duration, material composition, and biological safety endpoints.

2. Why Biocompatibility Testing Matters for Transdermal Patches

A transdermal patch is in direct, prolonged contact with the skin—typically for 8–24 hours at a time. Every component that touches the skin must be safe:

• Backing layer — non-woven fabric, film, or hybrid material
• Adhesive layer — pressure-sensitive adhesive (PSA) containing active and inactive ingredients
• Active ingredients — drug compounds, botanical extracts, or other active substances
• Release liner — siliconized paper or film removed before application
• Packaging materials — pouches, foil seals, cartons

Any of these materials can cause a biological response—irritation, sensitization, allergic reaction, or even systemic toxicity—if not properly evaluated and tested.

3. ISO 10993 Categories and Their Relevance to Transdermal Patches

ISO 10993 consists of over 20 parts. The following are most relevant to transdermal patches:

4. Contact Duration Categories

ISO 10993 categorizes medical devices by the duration of tissue contact. This determines which tests are required:

• Limited contact (≤ 24 hours) — applicable to most transdermal patches worn for a single day
• Prolonged contact (24 hours – 30 days) — applicable to patches worn continuously for multiple days
• Long-term contact (> 30 days) — rare for patches; would require the most extensive testing

Most standard pain relief patches and slimming patches fall into the limited contact category, but OEM buyers with special formulations or extended-wear designs should confirm their patch classification with their supplier.

5. The ISO 10993 Testing Process for Transdermal Patches

Step 1: Chemical Characterization (ISO 10993-18)

Before any biological testing begins, the complete chemical composition of the patch must be documented. This includes:

• Full list of all raw materials
• Adhesive composition and coating weight
• Active ingredient identity and concentration
• Residual solvents, monomers, or degradation products

Step 2: In Vitro Cytotoxicity Testing (ISO 10993-5)

Liquid extracts of the patch materials are applied to cell cultures to detect any cytotoxic (cell-killing) effects. This is typically the first test performed and is highly sensitive.

Step 3: Skin Sensitization Testing (ISO 10993-10)

Using animal-free in chemico or in vitro methods (where possible), patches are evaluated for their potential to cause allergic skin reactions. This is particularly important for patches containing botanical extracts or essential oils.

Step 4: Skin Irritation Testing (ISO 10993-23)

Patches are applied to animal skin or reconstructed human skin models under realistic wear conditions to evaluate irritation potential. Test duration and patch size must replicate actual use conditions.

Step 5: Risk Assessment and Reporting

All test results are compiled into a Biological Evaluation Plan (BEP) and Biological Evaluation Report (BER). These documents are required for CE Marking, FDA submissions, and OEM buyer qualification.

6. Key Testing Requirements Summary

7. What OEM Buyers Should Ask Their Supplier

Before placing an order, request the following documentation from your transdermal patch supplier:

1. Biological Evaluation Report (BER) — confirming all required ISO 10993 tests have been performed
2. Test reports from accredited laboratories — look for GLP (Good Laboratory Practice) certified labs
3. Chemical characterization data — full material disclosure
4. ISO 13485 certificate — quality management system certification
5. Declaration of Conformity — supplier's declaration of compliance with ISO 10993

Red flag: If a supplier cannot provide a BER or claims testing is "not necessary" for your product type, this is a serious compliance risk. Walk away.

8. KONGDY's ISO 10993 Compliance Commitment

At KONGDY (manufactured by Henan Kangdi Medical Devices Co., LTD), biocompatibility testing is a standard part of our OEM quality assurance process. We work with GLP-certified testing laboratories to ensure every patch formulation meets ISO 10993 requirements before it reaches your market.

Our compliance advantages:

• Full ISO 10993-18 chemical characterization — complete material disclosure for every formula
• Accredited in vitro cytotoxicity testing — cell-based screening for every batch
• Skin sensitization and irritation testing — GLP-certified lab reports available
• Comprehensive BER documentation — ready for CE Marking and FDA submissions
• ISO 13485 + TÜV certification — quality management you can trust
• Custom test programs — we design testing based on your specific market and regulatory requirements
• Low MOQ starting at 100 pieces — quality testing accessible for brands of all sizes

9. Conclusion

ISO 10993 biocompatibility testing is non-negotiable for any transdermal patch entering regulated markets. Understanding which tests apply to your product—and demanding proper documentation from your supplier—is the single most effective way to protect your brand, your customers, and your regulatory status.

Whether you're sourcing pain relief patches, slimming patches, or custom transdermal formulations, KONGDY has the testing infrastructure, quality systems, and regulatory expertise to support your compliance journey.

Need ISO 10993 documentation or a custom test program?
Email: hnkangdi888@hotmail.com
WhatsApp: +86 15517541011
Website: www.kangdimedical.com